Literature DB >> 24262022

An in vivo mouse model of metastatic human thyroid cancer.

Lisa Zhang1, Kelli Gaskins, Zhiya Yu, Yin Xiong, Maria J Merino, Electron Kebebew.   

Abstract

BACKGROUND: Mouse models of metastatic human cancers are important tools in preclinical studies for testing new systematic therapies and studying effectors of cancer metastasis. The major drawbacks of current mouse models for metastatic thyroid cancer are that they have low metastasis rates and do not allow in vivo tumor detection. Here, we report and characterize an in vivo detectable metastasis mouse model of human thyroid cancer using multiple thyroid cancer cell lines.
METHODS: Human anaplastic thyroid cancer cell lines 8505C, C-643, SW-1736, and THJ-16T; follicular thyroid cancer cell lines FTC-133, FTC-236, and FTC-238; and Hürthle cell carcinoma cell line XTC-1 were transfected with a linearized pGL4.51[luc2/CMV/Neo] vector or transduced with lentivirus containing Luc2-eGFP reporter genes. The stably transfected cells were injected intravenously into NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ mice. Tumors were detected with an in vivo imaging system-Xenogen IVIS. Vemurafenib, a BRAF inhibitor, was used to treat lung metastases generated from 8505C-Luc2 cells with a BRAF(V600E) mutation to test the accuracy of the model to evaluate response to therapy.
RESULTS: Intravenous injection of as few as 30,000 8505C-Luc2 cells produced lung metastases in 100% of the injected mice, and many of these mice also developed bone metastases at a later stage of the disease. Similarly, metastatic tumors also developed in all mice injected with C-643-Luc2, THJ-16T-Luc2, FTC-133-Luc2, FTC-236-Luc2, FTC-238-Luc2, and XTC-1-Luc2 cells. The metastases were easily detectable in vivo, and tumor progression could be dynamically and accurately followed and correlated with the actual tumor burden. Furthermore, disease progression could be easily controlled by adjusting the number of injected cells. The in vivo treatment of 8505C xenograft lung metastases with vemurafenib dramatically reduced the growth and signal intensity with good correlation with actual tumor burden.
CONCLUSIONS: Herein we report an in vivo detectable mouse model of metastatic human thyroid cancer that is reliable and reproducible. It will serve as a useful tool in the preclinical testing of alternative systematic therapies for metastatic thyroid cancer, and for functional studies of thyroid cancer tumor biology in vivo.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24262022      PMCID: PMC3993065          DOI: 10.1089/thy.2013.0149

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  24 in total

1.  SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.

Authors:  Won Gu Kim; Celine J Guigon; Laura Fozzatti; Jeong Won Park; Changxue Lu; Mark C Willingham; Sheue-yann Cheng
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

Review 2.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

Review 3.  Genetic alterations in thyroid cancer: the role of mouse models.

Authors:  K A B Knostman; S M Jhiang; C C Capen
Journal:  Vet Pathol       Date:  2007-01       Impact factor: 2.221

4.  Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.

Authors:  Matthew A Nehs; Carmelo Nucera; Sushruta S Nagarkatti; Peter M Sadow; Dieter Morales-Garcia; Richard A Hodin; Sareh Parangi
Journal:  Endocrinology       Date:  2011-12-27       Impact factor: 4.736

Review 5.  Follicular thyroid cancer cells: a model of metastatic tumor in vitro (review).

Authors:  T Hoelting; P E Goretzki; Q Y Duh
Journal:  Oncol Rep       Date:  2001 Jan-Feb       Impact factor: 3.906

Review 6.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Authors:  R C Smallridge; J A Copland
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-24       Impact factor: 4.126

7.  An orthotopic model of papillary thyroid carcinoma in athymic nude mice.

Authors:  Soon-Hyun Ahn; Ying Henderson; Ya'an Kang; Chandrani Chattopadhyay; Paula Holton; Mary Wang; Katrina Briggs; Gary L Clayman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-02

8.  Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables.

Authors:  J J Ruegemer; I D Hay; E J Bergstralh; J J Ryan; K P Offord; C A Gorman
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

9.  Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells.

Authors:  Z Dong; R Radinsky; D Fan; R Tsan; C D Bucana; C Wilmanns; I J Fidler
Journal:  J Natl Cancer Inst       Date:  1994-06-15       Impact factor: 13.506

10.  Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.

Authors:  Christine M Chan; Xia Jing; Laura A Pike; Qiong Zhou; Dong-Jun Lim; Sharon B Sams; Gregory S Lund; Vibha Sharma; Bryan R Haugen; Rebecca E Schweppe
Journal:  Clin Cancer Res       Date:  2012-05-14       Impact factor: 12.531

View more
  27 in total

1.  Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Authors:  Myriem Boufraqech; Dhaval Patel; Naris Nilubol; Astin Powers; Timothy King; Jasmine Shell; Justin Lack; Lisa Zhang; Sudheer Kumar Gara; Viswanath Gunda; Joanna Klubo-Gwiezdzinska; Suresh Kumar; James Fagin; Jeffrey Knauf; Sareh Parangi; David Venzon; Martha Quezado; Electron Kebebew
Journal:  Thyroid       Date:  2018-12-28       Impact factor: 6.568

Review 2.  Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.

Authors:  Neal Smith; Carmelo Nucera
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

3.  A Fluorescent, [18F]-Positron-Emitting Agent for Imaging Prostate-Specific Membrane Antigen Allows Genetic Reporting in Adoptively Transferred, Genetically Modified Cells.

Authors:  Hua Guo; Harikrishna Kommidi; Yogindra Vedvyas; Jaclyn E McCloskey; Weiqi Zhang; Nandi Chen; Fuad Nurili; Amy P Wu; Haluk B Sayman; Oguz Akin; Erik A Rodriguez; Omer Aras; Moonsoo M Jin; Richard Ting
Journal:  ACS Chem Biol       Date:  2019-06-17       Impact factor: 5.100

4.  Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors.

Authors:  Yogindra Vedvyas; Enda Shevlin; Marjan Zaman; Irene M Min; Alejandro Amor-Coarasa; Spencer Park; Susan Park; Keon-Woo Kwon; Turner Smith; Yonghua Luo; Dohyun Kim; Young Kim; Benedict Law; Richard Ting; John Babich; Moonsoo M Jin
Journal:  JCI Insight       Date:  2016-11-17

Review 5.  Mouse models of thyroid cancer: A 2015 update.

Authors:  Lawrence S Kirschner; Zahida Qamri; Suresh Kari; Amruta Ashtekar
Journal:  Mol Cell Endocrinol       Date:  2015-06-27       Impact factor: 4.102

Review 6.  Animal Models of Bone Metastasis.

Authors:  J K Simmons; B E Hildreth; W Supsavhad; S M Elshafae; B B Hassan; W P Dirksen; R E Toribio; T J Rosol
Journal:  Vet Pathol       Date:  2015-05-28       Impact factor: 2.221

7.  Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.

Authors:  Shweta Kotian; Lisa Zhang; Myriem Boufraqech; Kelli Gaskins; Sudheer Kumar Gara; Martha Quezado; Naris Nilubol; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2017-06-09       Impact factor: 12.531

8.  miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Authors:  Myriem Boufraqech; Naris Nilubol; Lisa Zhang; Sudheer Kumar Gara; Samira M Sadowski; Amit Mehta; Mei He; Sean Davis; Jennifer Dreiling; John A Copland; Robert C Smallridge; Martha M Quezado; Electron Kebebew
Journal:  Cancer Res       Date:  2014-12-08       Impact factor: 12.701

9.  Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.

Authors:  Myriem Boufraqech; Lisa Zhang; Naris Nilubol; Samira M Sadowski; Shweta Kotian; Martha Quezado; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2016-03-30       Impact factor: 12.531

10.  Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.

Authors:  Naris Nilubol; ZiQiang Yuan; Giulio F Paciotti; Lawrence Tamarkin; Carmen Sanchez; Kelli Gaskins; Esther M Freedman; Shugeng Cao; Jielu Zhao; David G I Kingston; Steven K Libutti; Electron Kebebew
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.